99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma
Open Access
- 15 August 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (8) , e0160714
Abstract
The aim of this study was to assess the utility of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 scintigraphy in the management of patients with hypoglycemia, particularly in the detection of occult insulinoma. Forty patients with hypoglycemia and increased/confusing results of serum insulin and C-peptide concentration and negative/inconclusive results of other imaging examinations were enrolled in the study. In all patients GLP-1 receptor imaging was performed to localise potential pancreatic lesions. Positive results of GLP-1 scintigraphy were observed in 28 patients. In 18 patients postsurgical histopathological examination confirmed diagnosis of insulinoma. Two patients had contraindications to the surgery, one patient did not want to be operated. One patient, who presented with postprandial hypoglycemia, with positive result of GLP-1 imaging was not qualified for surgery and is in the observational group. Eight patients were lost for follow up, among them 6 patients with positive GLP-1 scintigraphy result. One patient with negative scintigraphy was diagnosed with malignant insulinoma. In two patients with negative scintigraphy Munchausen syndrome was diagnosed (patients were taking insulin). Other seven patients with negative results of 99mTcGLP-1 scintigraphy and postprandial hypoglycemia with C-peptide and insulin levels within the limits of normal ranges are in the observational group. We would like to mention that 99mTc-GLP1-SPECT/CT was also performed in 3 pts with nesidioblastosis (revealing diffuse tracer uptake in two and a focal lesion in one case) and in two patients with malignant insulinoma (with the a focal uptake in the localization of a removed pancreatic headin one case and negative GLP-1 1 scintigraphy in the other patient). 99mTc-GLP1-SPECT/CT could be helpful examination in the management of patients with hypoglycemia enabling proper localization of the pancreatic lesion and effective surgical treatment. This imaging technique may eliminate the need to perform invasive procedures in case of occult insulinoma.Keywords
This publication has 33 references indexed in Scilit:
- Post‐gastric bypass hypoglycaemia: a reviewClinical Endocrinology, 2016
- A short history of neuroendocrine tumours and their peptide hormonesBest Practice & Research Clinical Endocrinology & Metabolism, 2016
- Preoperative localization of an insulinoma: selective arterial calcium stimulation test performanceJournal of Endocrinological Investigation, 2015
- Detection of Metastatic Insulinoma by Positron Emission Tomography With [68Ga]Exendin-4—A Case ReportThe Journal of Clinical Endocrinology & Metabolism, 2014
- Peptide-Based Probes for Cancer ImagingJournal of Nuclear Medicine, 2008
- Non‐insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacksClinical Endocrinology, 2008
- Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: A diagnostic and therapeutic challengeSurgery, 2007
- Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targetingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy VolunteersThe Journal of Clinical Endocrinology & Metabolism, 2002
- Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humansAmerican Journal of Physiology-Endocrinology and Metabolism, 1997